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AN ExPlorAtory ANAlysis of thE AssoCiAtioN BEtwEEN EortC-QlQ 
C30 DomAiNs AND ProgrEssioN frEE/ovErAll survivAl iN ADvANCED 
mElANomA AftEr 12 wEEks of trEAtmENt oN iPilimumAB ComPArED to 
gP100 iN A PhAsE iii CliNiCAl triAl
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Objectives: This study analyses the association between health-related quality 
of life (HRQL) domains and progression free (PFS) and overall survival (OS) for ipili-
mumab, ipilimumab + gp100, and gp100 alone during the 12 week treatment induc-
tion period compared to baseline. The aim of this study was to assess whether 
outcomes reported in the EORTC-QLQ-C30 summary domains impact the hazard 
of progressing and/or dying after 12 weeks of treatment. MethOds: Data from the 
MDX010-20 trial, including 676 previously treated patients with unresectable stage 
III or IV melanoma, was analysed. A domain correlation plot (excluding Global 
domain) was constructed to determine whether the EORTC-QLQ-C30 domains 
showed a high level of correlation for baseline scores. It was then used to derive 
two components summarising fourteen domain scores, Principal Components 
1, containing 10 domain scores (Pain, Appetite Loss, Nausea, Finance, Dyspnoea, 
Constipation, Diarrhoea, Role, Social and Physical) and 2 containing 4 domains 
scores (Fatigue, Sleep Disturbance, Emotional and Cognitive), based on the cor-
relation level between domains. These two Principal Components were entered as 
additional covariates in the Cox model for PFS/OS and hazard ratios were deter-
mined. Results: In the Cox regression model, Principal Component 1 showed a 
30% increase in hazard of progression when comparing the upper to the lower 
quartile of the Principal Component score , while a lower Principal Component 
1 score indicated a better HRQL at baseline. It was also showed a rate of death 
twice as high in the upper quartile than the lower quartile. Principal Component 
2 neither affected significantly PFS nor OS. cOnclusiOns: In advanced mela-
noma treated by ipilimumab compared to gp100, PFS and OS were associated with 
most of the HRQL domain scores. These findings suggest that poor baseline HRQL 
could be predictive of poor PFS/OS, while higher baseline HRQL could predict a 
better outcome.
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thE hArow stuDy
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Objectives: The optimal treatment choice for preserving QoL of the about 64,000 
men diagnosed with prostate cancer each year in Germany still remains unclear. The 
objectives therefore were to generate long-term information under day-to-day condi-
tions on QoL of men in Germany cared for newly diagnosed LCLRPC using hormonal 
therapy (HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watch-
ful waiting (WW) – HAROW. MethOds: The long-term observational multi-centre 
HAROW study was undertaken. The urologist provided all relevant clinical data of 
the patient. The patient provided inter alia data on QoL using the EQ-5D. Utilities 
derived from the EQ-5D based on the German value set were used to construct quality-
adjusted life-years (QALYs). QALYs were discounted by 3% annually and standardised 
to mean QALYs per patient-year (PY) for each initial treatment strategy. Differences 
between strategies were tested using the Kruskal-Wallis test (Bonferroni-corrected 
p= 0.0018 due to 28 tests). Results: Between July 2008 and March 2013, 3063 patients 
(mean age 67.3 ± 7.5 years) with LCLRPC (T1a–T2c, N0, M0) were included from 257 
urologists. Data on QoL were documented by patients as follows (% of patients/strat-
egy): AS n= 353 (78%), RT n= 291 (77%), HT n= 149 (71%), HT+RT n= 68 (85%), combination 
therapy (CT) n= 109 (80%), OP n= 1167 (71%), other therapy (OT) n= 9 (50%), WW n= 93 
(66%), over a mean time of between 1.6 (OT) and 2.5 years (CT). AS showed the highest 
undiscounted/discounted QALYs/PY (0.9297/0.9103) followed by OP (0.9289/0.9075), 
RT (0.9075/0.8878), CT (0.9071/0.8820), OT (0.8954/0.8818), HT+RT (0.8875/0.8699), WW 
(0.8646/0.8465), and HT (0.8485/0.8292). Compared to HT, QALYs/PY were significantly 
higher with AS (p< 0.0001), with OP (p< 0.0001), and with RT (p= 0.0002). Tests with 
undiscounted/discounted QALYs/PY adjusted for age, tumor stage and comorbidity 
showed no different results. cOnclusiOns: According to the HAROW study, active 
surveillance yielded the highest QALYs of the different LCLRPC treatment strategies 
in Germany evaluated.
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Objectives: To explore how often and which types of quality of life (QOL) data are 
included in the dossiers submitted for the AMNOG early benefit assessment and 
analyze how a drug’s effect in QOL is interpreted by the industry and the evaluating 
committee. MethOds: The published value dossiers up to June 15, 2013 and the cor-
responding benefit assessments were reviewed. Types of QOL data and the statements 
concerning QOL in the value dossier and the benefit assessments were collected and 
summarized. Results: A total of 46 cases were analyzed. In 6 cases no dossier was 
submitted. Of the rest, 13 dossiers (32.5%) did not include any QOL data, 13 (32.5%) 
included disease-specific QOL data only, 5 (12.5%) included generic QOL data only, 
and 9 (22.5%) both types. The QOL instruments used were considered as valid by the 
assessors. However, outcomes such as pain severity, fatigue, work productivity, and 
health care resource use were not regarded as QOL measures. Of 27 dossiers that have 
included QOL data companies have claimed an added benefit in QOL, either for the 
whole population or a specific subgroup, in 15 (56%) cases. However, the assessors rec-
of care could be nowadays a major issue MethOds: This prospective study carried 
out in 12 Hospitals. At baseline patients fulfilled EQ-5D questionnaire (utility and 
VAS scale), EORTC-QLQ-C30 (physical, role, emotional, cognitive and social function-
ing, and global health) and HADS. One year post-surgical management they com-
pleted the EQ-5D and EORTC-QLQ-C30. We used general linear models to establish 
the influence of baseline anxiety (HADS-A) and depression (HADS-D) on changes in 
HRQoL, adjusted by baseline score and gender. We have used the recommended cut-
off points of HADS ≤ 7 (normal); 8-10 (uncertain) and ≥ 11 (problem). Results: There 
were 778 patients. The mean age (SD) was 67.4 (10.4). Males represented the 62.7%. 
At baseline, in the HADS-A there were 282 (36.4%) of patients scoring higher than 7 
points (17.6% higher than 10 points). In the HADS-D 137 (17.6%) scored higher than 7 
and 9.3% were higher than 10 points. Both anxiety and depression at baseline influ-
ence the changes in EQ-5D, with less gains in patients with more level of anxiety 
or depression (p< 0.0001). Regarding the EORTC-QLQ-C30 domains, baseline anxiety 
level impacts significantly in all domains, except in physical functioning, with gains 
around 5 to 11 points lower in patients with anxiety problems comparing with those 
classified as normal (all p< 0.05). Baseline depression level impacts significantly on 
changes in role and social functioning, and global health, with gains around 10 to 
13 points lower in patients with depression problems (all p< 0.01). cOnclusiOns: 
This study supports the importance of providing psychological interventions for 
cancer patients before surgical management.
PCN168
A ProPosED 6-itEm rEDuCtioN for thE EuroPEAN orgANizAtioN for thE 
rEsEArCh AND trEAtmENt of CANCEr-QuAlity of CorE QuEstioNNAirE 
(EortC QlQ-C30) - CuBAN grouP of triAlists oN EPiDErmAl growth 
fACtor (Cgt-Egf)
Viada C.1, Ballesteros J.2, Fors M.3, Luaces P.1, Sánchez L.1, Crombet T.1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country UPV/EHU, 
Leioa, Spain, 3National Coordinating Centre of Clinical Trials, Havana, Cuba
Objectives: To develop an unidimensional and short version of the QLQ-C30 to be 
used as a patient-perceived quality of life in cancer trials. MethOds: We analysed 
data of 873 patients diagnosed with non-small-cell lung cancer who participated 
in 4 Cuban multicenter trials of immunotherapy against the epidermal growth 
factor. The analysis followed a 4-step approach. First, we conducted a Mokken 
nonparametric item response analysis to ascertain the QLQ-C30 dimensionality 
and separate several scales if appropriate. Second, we conducted a parametric 
Samejima’s graded response model (GRM) to assess the item characteristics and 
information. Third, we did a confirmatory factor analysis (CFA) to test the scales 
unidimensionality and to obtain standardised factor loadings to suggest a reduced 
version of the QLQ. Finally, we assessed the discriminative validity of the reduced 
version by using receiver-operator curve (ROC) analysis. Results: Mokken analy-
sis of the QLQ-C30 resulted in a unidimensional scale, with an overall scalability 
of 0.43 that defined a medium scale. The unconstrained GRM showed that most 
items presented appropriate difficulty and discrimination parameters. The CFA 
supported an underlying unidimensional latent structure for the whole QLQ-C30 
(CFI = 0.98; RMSEA = 0.05) with modification indexes pointing to important redun-
dancy of information. The selection of items with standardized factor loadings 
> 0.70 lead to a 6-item QLQ that showed good discriminative validity against 
independent criteria of quality of life (ROC area = 0.76; 95% CI = 0.72 to 0.80) as 
compared with the values for the whole scale (ROC area = 0.70; 95% CI = 0.66 to 
0.74). cOnclusiOns: The EORTC QLQ-C6 suggested in this study presents good 
psychometric properties and includes an unidimensional structure of patient-
perceived quality of life.
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Objectives: To evaluate the burden of BM on patients with CRPC and their treat-
ing physicians. MethOds: A total of 167 physicians (100 oncologists and 67 urolo-
gists) completed a prospective 5-day workload form, interview and average of 8 
patient record forms (PRFs, October 2012–March 2013) for non-metastatic and 
metastatic CRPC patients. Data from 142 workload forms, 167 interviews and 1,274 
PRFs (including 475 CRPC patients at ‘high risk’ of BM, 505 CRPC patients with BM 
only, 102 CRPC patients with BM and VM and 192 CRPC patients with VM only) 
were included in these analyses. Results: Physician interviews showed 92%, 
63% and 60% of the physicians believed the greatest patient burden of BM was 
back pain, reduced ability to perform daily activities and fractures, respectively 
(from a predetermined list where ‘other’ was specified). PRF data confirmed that 
Eastern Cooperative Oncology Group (ECOG) performance status was significantly 
worse in patients with BM (with/without VM) when compared with patients at 
high-risk of developing BM (p< 0.0001). 92% of the patients at ‘high-risk’ (defined by 
treating physician) of developing BM (n= 475) had a PSA doubling time (PSADT) ≤ 6 
months. The biggest burden of BM on treating physicians was seeing patient dete-
rioration (70% [n= 117]; 67% of oncologists; 75% of urologists), inability to propose 
effective treatment (57% [n= 95]; 60% of oncologists; 52% of urologists), managing 
complex regimens (29% [n= 49]; 27% of oncologists; 33% of urologists) and trans-
ferring patients for respite/hospice care (23% [n= 38]; 26% of oncologists; 18% of 
urologists). cOnclusiOns: These data highlight the burden of BM on patients 
with CRPC and the perceived burden on physicians treating this population. BM 
are associated with a significant reduction in patients’ performance status and 
an increased burden on the patient. There is a need for treatments to prevent or 
delay the onset of BM and their associated burden.
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were included and assessed with respect to their evidence for special subgroups. 
Regulatory guidelines were compared against the IQWIG evaluation methods 
with respect to the handling of subgroups and its impact on the clinical benefit 
assessment. Furthermore GBA decisions and potential price impact with the GKV-
Spitzenverband are taken into account for the pricing impact of new evidence 
with special subgroups based on target profiles developed. Results: Overall, ten 
new compounds were approved by the EMA in the last 2.5 years for which no 
subgroup trials were presented. Regulatory guidelines and IQWIG methods differ 
significantly with respect to subgroup handling from a statistical and health policy 
perspective. Most important clinical trials with a special focus on subgroups of 
interest could even have a negative outcome on the market access of such a com-
pound with respect to subgroup-only reimbursement (in case of positive subgroup 
results) or exclusion of subgroups (in case of negative results) based on target 
profiles included in the analyses. cOnclusiOns: Incentives from a health policy 
and investment decision perspective are low for the pharmaceutical industry in 
terms of research focus towards subgroups of special interest. Further research 
with respect to incentives is needed.
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Objectives: To identify the extent to which current approaches to clinical devel-
opment, regulatory assessment, and economic evaluation of personalised health 
care drugs in oncology are aligned with real world clinical practice at product 
launch. To identify and critically evaluate alternative approaches that should be 
factored into future clinical development and health technology assessment (HTA) 
planning. MethOds: Structured interviews were undertaken with physicians and 
payers (n= 50) to identify the key issues surrounding the phased development and 
early use of personalised health care drugs in oncology. Analogue analyses were 
undertaken, based on “treatment tracking”, to develop a comparison between 
theoretical RCT (randomised control trial) evidence based, licensure aligned, uti-
lisation and that observed in real world clinical practice Gap Analyses identified 
drivers of differences. The utility and limitations of retrospective and prospective 
observational registries in addressing these were explored. Results: Early results 
indicate that the level of unmet need, the magnitude of incremental clinical ben-
efit, the timing of biomarker testing in the treatment algorithm and, increasingly, 
the number and prioritisation of diagnostic tests for an increasing number of dif-
ferent biomarkers are drivers of real world utilisation. Differences exist between 
countries. The greatest differences between theoretical and real world utilisation 
are in markets where decisions are driven by considerations of relative clinical 
effectiveness rather than cost effectiveness. Comparative SWOT analyses were 
developed of current and alternative clinical development, regulatory and health 
technology assessment systems. These highlight areas where improvements in 
approach would be beneficial. cOnclusiOns: Additional evidence sources should 
be used to reinforce the regulatory and health technology assessment of PHC 
products in oncology with the aim of bringing closer alignment between the RCT 
approach to drug development and assessment – and the utilisation and outcomes 
(economic, clinical, and humanistic) seen in real-world clinical practice.
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Objectives: The overall goal of our project is to adapt an Austrian decision-analytic 
model for the treatment of chronic myeloid leukemia (CML) to the U.S. context. We 
conducted an electronic survey to gain expert knowledge about the state-of-the-
art in CML treatment. MethOds: The expert survey was constructed as an online 
questionnaire and contained 14 questions. The questionnaire was developed in col-
laboration with ONCOTYROL project partners and distributed to CML experts at the 
Huntsman Cancer Institute in Utah. Data were generated using Qualtrics and dis-
cussed with experts in order to incorporate the findings into the model. Results: 
Four out of six experts (67%) stated that effectiveness of second-line TKI depends 
on the response to first-line TKI therapy. NCCN and ELN guidelines are the most fre-
quently used guidelines when treating CML patients. Furthermore, expert opinion, 
literature and personal characteristics influence decision making. Patients younger 
than 50, or between 50 and 54 years, most frequently receive stem cell transplanta-
tion after TKI failure. The recently approved TKIs bosutinib and ponatinib are used 
by 17% and 100% respectively. Experts stated that quality of life (QoL) on dasatinib 
is better (17%)/ about the same (50%)/ worse (33%) compared to imatinib. QoL on 
nilotinib is better (17%)/ about the same (83%) in comparison to imatinib. QoL on 
ponatinib is better (17%)/ about the same (67%)/ worse (17%) compared to imatinib. 
Although bosutinib is rarely (67%) used, experts answered that is better (17%) or 
about the same (17%) compared to imatinib. cOnclusiOns: The results provide 
valuable insights into the state-of-the-art of CML treatment in the U.S. context. Due 
to the small sample size and the limitation to the region of Utah, results should 
be interpreted carefully. However, the responses for ponatinib and bosutinib are 
particularly valuable for the model due to lack of QoL and long-term data.
ognized the added benefit claim in 2 cases only. In an additional 2 cases no clear scor-
ing was provided for the QOL outcome and in the remaining 11 cases no additional 
benefit was acknowledged. The main reasons were missing statistical significance 
of results or the submitted QOL data were regarded as not usable. cOnclusiOns: 
In a majority of value dossiers companies included QOL data and also most often 
claimed an added benefit in QOL. However, the assessors have accepted this added 
value in exceptional cases only. In order to get an added value recognized showing 
both statistical and clinical significance of results is required.
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Objectives: To investigate the feasibility of a online survey using social media 
(facebook) to estimate the willingness to pay (WTP) for a new diagnostic blood 
test to determine the risk of colorectal cancer. According to the approval docu-
ments of the manufacturer the new biomarker test shows a better performance, 
better handling and improved compliance of patients and physicians compared 
to standard fecal occult blood tests (FOBT). MethOds: A standardized question-
naire was accompanied by background information on colorectal cancer and 
alternative screening approaches. WTP was asked for in categories (e.g. < 100 or 
> 100 EUR) and maximum values. Other parameters such as age, sex, insurance 
status, income, family history of cancer and risk factors were determined in 
categories. The survey ran for 14 days in November 2012 and was started via 6 
facebook accounts with the possibility of further distribution. Results: Overall 
123 completed questionnaires were submitted anonymously. The average age 
was 24,2 years and in 94% the monthly income was below 1500 EUR due to their 
student status. 68% of the participants had cases of cancer in the family and 
36% knew about the colorectal cancer. The most important quality aspects of 
screening tests for were accuracy (69%), handling (14%), price (11%) and the time 
to result (6%). 24% stated that their WTP is lower than 100EUR and the mean WTP 
for S9 was 271EUR. Higher income, family history of colorectal cancer and private 
insurance status were positively correlated with a higher WTP. cOnclusiOns: 
WTP and patient preference studies via social networks such as facebook are fea-
sible, easy to perform and reveal plausible results. Advantages of online surveys 
in social networks are that the results are gained voluntarily and anonymously 
avoiding interviewer bias. Disadvantages obviously lie in a selection of young 
and healthy populations.
CANCEr – health Care use & Policy studies
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Objectives: Recently a major cancer center in the United States decided not to 
offer treatment using a newly launched oncology drug citing comparative effective-
ness and cost as reasons. This study looked at health care consumer opinions about 
the decision to restrict treatment options based on outcomes and price. MethOds: 
The nationally representative Truven Health PULSE Healthcare Survey gathered 
responses from 2,615 US households via landline telephone, cell phone or Internet. 
Respondents were asked their opinion regarding a decision by providers not to offer a 
new cancer treatment because it demonstrated the same benefit as an existing drug 
with the same side effects, but its cost was higher. Demographic data were gathered 
and respondents were asked if they are being/have been treated for cancer, and if a 
friend, family member or loved one is being/has been treated for cancer. Results: 
Overall, 40.5% of respondents agreed with the decision; 37.5% disagreed. Agreement 
with the decision varied with the respondents’ exposure to cancer. Those who had 
a family member, friend or loved one with cancer were least likely to agree (36%), 
while those who not only had a family member, friend or loved one with cancer, but 
also had cancer themselves were the most likely to agree (50.8%). Respondents who 
had cancer themselves with no family member, friend or loved one with cancer or 
had no experience with cancer were equally likely to agree with the decision (44%) 
(P< 0.0001). cOnclusiOns: Findings suggest that fear and experience may play roles 
in consumers’ opinions regarding restrictions on cancer medications. Individuals who 
have experienced cancer may place more value on outcomes, side effects, and/or out-
of-pocket costs than those with no personal experience or may have more realistic 
expectations for treatment. Additional research is warranted to better understand the 
drivers of consumer opinion regarding cancer treatment coverage decisions.
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Objectives: Definition of target profiles for new compounds and lifecycle plan-
ning lead to clinical studies in the context of a clinical trial program. Currently 
subgroups of special interest such as elderly, pediatrics or females/males are nor-
mally not separately included in these research programmes, most of the time 
not even stratified for. The objective of this research is to analyze the inclusion of 
patient-relevant endpoints in special patient subgroups during the clinical trial 
programme which would thereafter increase the pricing opportunity of this new 
compound in the German market. MethOds: New oncology therapies which 
were authorized by the European Medicine Agency (EMA) after January 1, 2011 
